Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Evidence for pre-existing myeloma cells with a gene expression pattern associated with resistance to BCMA CAR T cells.

Angelica Amanso, Karanpreet Bhatia, Mackenzie Mekler, James Ackley, Pankoj Das, London Harper, Holly Lee, Madhav Dhodapkar, Stanley Riddell, Paola Neri, Nizar Bahlis, Sagar Lonial, Adam Marcus, Lawrence Boise

Blood (2025) 146 (Supplement 1): 1031.

https://doi.org/10.1182/blood-2025-1031

Published: 2025

Journal Articles

Antigen-dependent clonal sweep with sequential or combinatory anti-myeloma T cell engagers

Blood (2025) 146 (Supplement 1): 1030.

https://doi.org/10.1182/blood-2025-1030

Published: 2025

Journal Articles

Identify high-risk disease in multiple myeloma through single-cell transcriptomic detection of highly proliferative (PR) cells

Noemie Leblay, Sungwoo Ahn, Alexandra Poos, Mehmet Samur, Sheri Skerget, Holly Lee, Mansour Poorebrahim, David Jung, Sacha Benaoudia, Daniel Penaherrera, Herve Avet-Loiseau, Jonathan Keats, Nikhil Munshi, Niels Weinhold, Nizar Bahlis, Paola Neri

Blood (2025) 146 (Supplement 1): 2163.

https://doi.org/10.1182/blood-2025-2163

Published: 2025

Journal Articles

Enhancing immunotherapy efficacy in myeloma with a novel dual-action mitochondrial toxic peptide that overcomes resistance and induces immunogenic cell death.

Smriti Gurung, Colin Crean, David Halladay, judith Anderson, John Chirgwin, Holly Lee, Nizar Bahlis, Kelvin Lee, Attaya Suvannasankha

Blood (2025) 146 (Supplement 1): 3924.

https://doi.org/10.1182/blood-2025-3924

Published: 2025

Journal Articles

Deletion of TRAF3 and CYLD and NIK amplification activates NF-kb signalling and drives resistance to T cell based therapies in multiple myeloma by suppressing T cell activity

David Jung, Sacha Benaoudia, Holly Lee, Sungwoo Ahn, Sejal Chikhale, Mansour Poorebrahim, Noemie Leblay, Nizar Bahlis, Paola Neri

Blood (2025) 146 (Supplement 1): 803.

https://doi.org/10.1182/blood-2025-803

Published: 2025

Journal Articles

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D

Blood (2025) 146 (Supplement 1): 5785.

https://doi.org/10.1182/blood-2025-5785

Published: 2025

Journal Articles

Light-chain MGUS defined as per the revised definition of the istopmm study: Experience from the university of calgary MGUS clinic

Victor Jimenez-Zepeda, Holly Lee, Etienne Mahe, Sylvia McCulloch, Jason Tay, Peter Duggan

Blood (2025) 146 (Supplement 1): 2187.

https://doi.org/10.1182/blood-2025-2187

Published: 2025

Journal Articles

Enhanced efficacy of TRAIL or TRAIL-CD28 chimera armored anti-BCMA CAR T cells in multiple myeloma

Mansour Poorebrahim, David Jung, Holly Lee, Sacha Benaoudia, Sungwoo Ahn, Noemie Leblay, Sejal Chikhale, Elham Hasheminasabgo, Anja Barbour, Lawrence Boise, Paola Neri, Nizar Bahlis

Blood (2025) 146 (Supplement 1): 914.

https://doi.org/10.1182/blood-2025-914

Published: 2025

Journal Articles

Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma

Blood (2025) 146 (13): 1575–1585.

https://doi.org/10.1182/blood.2024028107

Published: 2025

Includes: Supplemental data

Journal Articles

Silence of the myeloma clones: GPRC5D epigenetic regulation

Holly Lee, Nizar J. Bahlis

Blood (2025) 146 (2): 133–135.

https://doi.org/10.1182/blood.2025028865

Published: 2025

Journal Articles

Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma

Holly Lee, Michael Durante, Sheri Skerget, Deeksha Vishwamitra, Sacha Benaoudia, Sungwoo Ahn, Mansour Poorebrahim, Elie Barakat, David Jung, Noémie Leblay, Bachisio Ziccheddu, Benjamin Diamond, Marios Papadimitriou, Adam D. Cohen, Ola Landgren, Paola Neri, Francesco Maura, Nizar J. Bahlis

Blood (2024) 144 (25): 2637–2651.

https://doi.org/10.1182/blood.2024026212

Published: 2024

Includes: Supplemental data

Journal Articles

BCMA Extracellular Domain Functional Hotspots and Resistance to Variable Anti-BCMA T Cell Engagers in Multiple Myeloma

Holly Lee, David Jung, Mansour Poorebrahim, Sacha Benaoudia, Sungwoo Ahn, Noémie Leblay, Eric Letouzé, Philippe Moreau, Herve Avet-Loiseau, Leo Rasche, Jonathan J Keats, Francesco Maura, Paola Neri, Nizar J. Bahlis

Blood (2024) 144 (Supplement 1): 4651.

https://doi.org/10.1182/blood-2024-211833

Published: 2024

Journal Articles

Immune and Tumor Mediators of Resistance to Daratumumab-IMiDs Based Therapies in Relapsed Multiple Myeloma

Noémie Leblay, Sungwoo Ahn, Holly Lee, Matteo Claudio Da Vià, Mansour Poorebrahim, Sacha Benaoudia, David Jung, Elham Hasheminasabgorji, Niccolò Bolli, Nizar J. Bahlis, Paola Neri

Blood (2024) 144 (Supplement 1): 4642.

https://doi.org/10.1182/blood-2024-208842

Published: 2024

Journal Articles

Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 247.

https://doi.org/10.1182/blood-2024-201288

Published: 2024

Journal Articles

Timing Antigenic Escape in Multiple Myeloma Treated with T-Cell Redirecting Immunotherapies

Marios Papadimitriou, Sungwoo Ahn, Benjamin Diamond, Holly Lee, John McIntyre, Marietta Truger, Michael Durante, Bachisio Ziccheddu, Ola Landgren, Leo Rasche, Nizar J. Bahlis, Paola Neri, Francesco Maura

Blood (2024) 144 (Supplement 1): 1899.

https://doi.org/10.1182/blood-2024-212294

Published: 2024

Journal Articles

Tumor Intrinsic and Antigen-Independent Resistance Mechanisms to Bispecific T Cell Engagers in Multiple Myeloma

Holly Lee, Sungwoo Ahn, Mansour Poorebrahim, David Jung, Sacha Benaoudia, Noémie Leblay, Francesco Maura, Lawrence H. Boise, Paola Neri, Nizar J. Bahlis

Blood (2024) 144 (Supplement 1): 1892.

https://doi.org/10.1182/blood-2024-211979

Published: 2024

Journal Articles

Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma

Blood (2024) 144 (Supplement 1): 592.

https://doi.org/10.1182/blood-2024-201056

Published: 2024

Journal Articles

NF-Kb Pathway Activation Driven By TRAF3 Loss Mediates Resistance to Anti-BCMA T-Cell Based Therapies in Multiple Myeloma

David Jung, Holly Lee, Sejal Chikhale, Mansour Poorebrahim, Sungwoo Ahn, Sacha Benaoudia, Noemie Leblay, Francesco Maura, Nizar J. Bahlis, Paola Neri

Blood (2024) 144 (Supplement 1): 591.

https://doi.org/10.1182/blood-2024-206347

Published: 2024

Journal Articles

BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms

Holly Lee, Paola Neri, Nizar J. Bahlis

Blood (2024) 143 (13): 1211–1217.

https://doi.org/10.1182/blood.2023022499

Published: 2024

Includes: Supplemental data

Journal Articles

Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency

Noémie Leblay, Sungwoo Ahn, Rémi Tilmont, Mansour Poorebrahim, Ranjan Maity, Holly Lee, Elie Barakat, Jean-Baptiste Alberge, Sarthak Sinha, Arzina Jaffer, Benjamin G. Barwick, Lawrence H. Boise, Nizar Bahlis, Paola Neri

Blood (2024) 143 (1): 42–56.

https://doi.org/10.1182/blood.2023020276

Published: 2024

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Evidence for pre-existing myeloma cells with a gene expression pattern associated with resistance to BCMA CAR T cells.

Antigen-dependent clonal sweep with sequential or combinatory anti-myeloma T cell engagers

Identify high-risk disease in multiple myeloma through single-cell transcriptomic detection of highly proliferative (PR) cells

Enhancing immunotherapy efficacy in myeloma with a novel dual-action mitochondrial toxic peptide that overcomes resistance and induces immunogenic cell death.

Deletion of TRAF3 and CYLD and NIK amplification activates NF-kb signalling and drives resistance to T cell based therapies in multiple myeloma by suppressing T cell activity

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D

Light-chain MGUS defined as per the revised definition of the istopmm study: Experience from the university of calgary MGUS clinic

Enhanced efficacy of TRAIL or TRAIL-CD28 chimera armored anti-BCMA CAR T cells in multiple myeloma

Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma

Silence of the myeloma clones: GPRC5D epigenetic regulation

Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma

BCMA Extracellular Domain Functional Hotspots and Resistance to Variable Anti-BCMA T Cell Engagers in Multiple Myeloma

Immune and Tumor Mediators of Resistance to Daratumumab-IMiDs Based Therapies in Relapsed Multiple Myeloma

Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma

Timing Antigenic Escape in Multiple Myeloma Treated with T-Cell Redirecting Immunotherapies

Tumor Intrinsic and Antigen-Independent Resistance Mechanisms to Bispecific T Cell Engagers in Multiple Myeloma

Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma

NF-Kb Pathway Activation Driven By TRAF3 Loss Mediates Resistance to Anti-BCMA T-Cell Based Therapies in Multiple Myeloma

BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms

Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only